Determination of Regulatory Review Period for Purposes of Patent Extension; NGENLA

Summary

The U.S. Food and Drug Administration (FDA) has determined the regulatory review period for NGENLA, a human biological product, due to patent extension applications submitted to the U.S. Patent and Trademark Office (USPTO).